Advertisement
UK markets close in 7 hours 7 minutes

  • FTSE 100

    8,385.96
    -30.49 (-0.36%)
     

  • FTSE 250

    20,700.03
    -83.34 (-0.40%)
     

  • AIM

    807.09
    0.00 (0.00%)
     

  • GBP/EUR

    1.1733
    +0.0027 (+0.23%)
     

  • GBP/USD

    1.2735
    +0.0024 (+0.19%)
     

  • Bitcoin GBP

    54,887.67
    -848.70 (-1.52%)
     

  • CMC Crypto 200

    1,466.65
    -59.77 (-3.92%)
     

  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     

  • DOW

    39,872.99
    +66.22 (+0.17%)
     

  • CRUDE OIL

    77.74
    -0.92 (-1.17%)
     

  • GOLD FUTURES

    2,419.60
    -6.30 (-0.26%)
     

  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     

  • HANG SENG

    19,197.68
    -22.94 (-0.12%)
     

  • DAX

    18,679.87
    -46.89 (-0.25%)
     

  • CAC 40

    8,101.03
    -40.43 (-0.50%)
     
Property:

The UK’s most expensive coastal town

Average home in this seaside town costs over £1m

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Nuvectis Pharma, Inc.
·1-min read
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

Event

36th Annual Roth Conference

Date

March 19, 2024

Time

8:00 AM Pacific Time (11:00 AM Eastern Time)

Link

https://wsw.com/webcast/roth48/nvct/1852019

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor currently undergoing a Phase 1a dose escalation study.

ADVERTISEMENT

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact

Christopher M. Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com